Jamie McCabe Dunn

Jamie McCabe Dunn obtained her PhD from the University of Pittsburgh under the supervision of Kay Brummond, followed by a postdoctoral position at the University of Colorado in the group of Andrew Phillips. Jamie began her career at Merck in process chemistry in 2009, where she made important contributions to clinical candidates for Alzheimer's disease (MK-8931) and diabetes, including support of pilot plant campaigns. In 2010 Jamie took the new challenge to joining Merck's Discovery Process Chemistry (DPC) group, where she developed novel chemistry to accelerate Medicinal Chemistry and driving successful transitions into clinical development in the areas of infectious disease and cardiometabolic diseases. In 2017, Jamie assumed the Process Chemistry lead role and cross-functional manufacturing team member for Bridion®, a reversal agent for two types of neuromuscular blocking agents used during surgery, with sales of >$1.2 billion in 2019. This work resulted in a promotion to Principal Scientist in 2018. Jamie is currently a Director, Process Chemistry in Rahway, NJ where she leads a group of process chemists in commercial route definition to support of the Merck small molecule portfolio. In addition to her noteworthy collection of scientific and pipeline accomplishments, Jamie has been awarded two ACS awards: the 2019 Rising Star of Medicinal Chemistry and the 2018 ACS Young Investigator Award. She currently sits on the editorial advisory board of the journal Organic Process Research and Development and is a co-editor in the special issue 'Celebrating Women in Process Chemistry.' Jamie has distinguished herself as the lead of the Small Molecule Process R&D Recruiting team, the lead of the Chemistry Awards Committee and through her membership and advocacy in the Women in Chemistry initiatives both internally and externally.